Trial Profile

58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tavapadon (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms TEMPO-4
Sponsors AbbVie; Cerevel Therapeutics

Most Recent Events

01 Nov 2024 Status changed from recruiting to active, no longer recruiting.
01 Aug 2024 According to an AbbVie media release, AbbVie has acquired Cerevel Therapeutics.
06 Sep 2023 Planned number of patients changed from 800 to 1200.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com